Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral dosage form for oral use. It treats partial‑onset seizures and epilepsy in patients who require additional seizure control.\n\nGNH India supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanilad, a sodium channel blocker, is employed in the management of seizure disorders.\n\nPartial‑onset seizures: helps reduce the frequency and severity of focal seizure episodes.\nEpilepsy (adjunctive therapy): improves overall seizure control when used with other antiepileptic drugs.\nRefractory focal epilepsy: offers an alternative option for patients whose seizures are not adequately controlled by other medications.

Lacosamide may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Dizziness\n- Headache\n- Nausea\n- Fatigue\n- Blurred vision\n- Diplopia\n\nSerious or Rare Side Effects:\n- Cardiac conduction abnormalities such as PR‑interval prolongation\n- Suicidal thoughts or behavior\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome)\n- Elevated liver enzymes\n- Hypersensitivity reactions including anaphylaxis\n- Respiratory depression in susceptible individuals.

When prescribing Kanilad, several safety considerations should be observed.\n\nRenal impairment: assess kidney function and adjust therapy if necessary.\nHepatic impairment: monitor liver enzymes and consider dose modification.\nConcomitant use with other sodium channel blockers: watch for additive central nervous system effects.\nPregnancy: use only if the potential benefit justifies the potential risk to the fetus.\nAvoid abrupt discontinuation: taper the dose under medical supervision to prevent seizure worsening.\nStore at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.\n- Co‑administration with other sodium channel blockers (e.g., carbamazepine): risk of additive CNS depression.\n- Drugs that prolong the PR interval (e.g., digoxin): may exacerbate cardiac conduction effects.\n\nModerate Interactions (Monitor Closely):\n- CYP2C19 substrates (e.g., omeprazole): may alter lacosamide metabolism.\n- Anticoagulants (e.g., warfarin): monitor INR and adjust dose as needed.\n- Alcohol: may enhance dizziness and sedation.